** Shares of precision oncology firm Black Diamond Therapeutics BDTX.O rise 35.1% to $2.26 premarket
** BDTX and French drugmaker Servier say they have entered into a licensing agreement for BDTX-4933, a small molecule designed by Black Diamond
** BDTX will receive an upfront payment of $70 million and will be eligible to receive up to $710 million in development and commercial sales milestone payments, along with tiered royalties based on global net sales
** Under the agreement, Servier will develop and commercialize BDTX-4933 for solid tumors including non-small cell lung cancer
** BDTX-4933 is currently in early-stage development
** Up to last close, BDTX has fallen 64.2% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。